Post-protocol therapy and informative censoring in the CANDOR study

Affiliations

¹ Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel.
² Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Divisions of Hematology and Medical Oncology, University of California San Francisco, San Francisco, CA, USA.
⁴ Division of Blood and Marrow Transplantation, University of California San Diego, CA, USA.
⁵ Division of Hematology and Hematological Malignancies, University of Utah, Salt Lake City, UT 84106, USA. Electronic address: g.mohyuddin@hci.utah.edu.

Free article

Comment

Tomer Meirson et al. Lancet Oncol. 2022 Mar.

Free article

. 2022 Mar;23(3):e97.

doi: 10.1016/S1470-2045(22)00075-4.

¹ Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel.
² Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Divisions of Hematology and Medical Oncology, University of California San Francisco, San Francisco, CA, USA.
⁴ Division of Blood and Marrow Transplantation, University of California San Diego, CA, USA.
⁵ Division of Hematology and Hematological Malignancies, University of Utah, Salt Lake City, UT 84106, USA. Electronic address: g.mohyuddin@hci.utah.edu.

No abstract available

Comment in

Post-protocol therapy and informative censoring in the CANDOR study - Authors' reply.
Usmani SZ, Li C, Obreja M, Dimopoulos M. Usmani SZ, et al. Lancet Oncol. 2022 Mar;23(3):e98. doi: 10.1016/S1470-2045(22)00077-8. Lancet Oncol. 2022. PMID: 35240099 No abstract available.

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M. Usmani SZ, et al. Lancet Oncol. 2022 Jan;23(1):65-76. doi: 10.1016/S1470-2045(21)00579-9. Epub 2021 Dec 3. Lancet Oncol. 2022. PMID: 34871550 Clinical Trial.